Communiqués

22/06 CTT Pharma Signs LOI for Clinical Trials and Testing of Nicotine Products AQ
17/06 CTT Pharma Signs LOI with European Company AQ
14/05 CTT Pharma Signs LOI with European Company AQ
02/12 CTT Pharma CEO Issues Letter to Shareholders AQ
20/11 CTT Pharma's CEO will issue a Letter to Shareholders AQ
10/09/25 CTT Pharma Signs Contract for $3 Million Equity Line of Credit AQ
10/06/25 CTT Pharma Grant Updates AQ
12/03/25 CTT Pharma's CEO Issues Letter to Shareholders AQ
22/01/25 CTT Pharma has engaged The OTC Markets to Uplist to The OTCQB AQ
07/01/25 CTT Pharma and Johns Hopkins University Submits Proposal For $15 Million NIH Grant For Smoking Cessation AQ
29/10/24 CTT Pharma's CEO Speaks at FDA and NIH Meeting for Advancing Smoking Cessation AQ
21/08/24 CTT Pharmaceuticals Holdings, Inc. Successfully Completes 2 Year PCAOB Audit AQ
15/07/24 CTT Pharmaceuticals Holdings, Inc. Signs Contract for 2 year PCAOB Audit AQ
25/06/24 CTT Pharma Gives Update on NSF Grant for Smoke Reduction Technology AQ
27/03/24 CTT Pharma Partners with Johns Hopkins University for NIH Grant for a Smoking Cessation Product AQ
28/03/23 CTT Pharma Appoints David Paton as Senior Advisor AQ
30/01/23 CTT Pharma Corporate Updates AQ
19/12/22 CTT Pharma Updates On Worldwide Patent Portfolio AQ
06/12/22 CTT Pharma Receives Approval for European Patent AQ
30/11/22 CTT Pharma Starts Product Development AQ
22/11/22 CTT Pharma Signs Agreement for New Oral Products AQ
14/11/22 CTT Pharma Will Utilize Patented Technology for Additional Oral Products AQ
12/10/22 CTT Pharma Files 2 USA Patents and 2 Canadian Patents AQ
03/10/22 CTT Pharma's CEO Issues Letter To Shareholders AQ
27/09/22 CTT Pharma Settles Lawsuit with Aurora AQ
Aucun résultat pour cette recherche